Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology

被引:85
|
作者
D'Alto, Michele [1 ]
Romeo, Emanuele [1 ]
Argiento, Paola [1 ]
Sarubbi, Berardo [1 ]
Santoro, Giuseppe [1 ]
Grimaldi, Nicola [1 ]
Correra, Anna [1 ]
Scognamiglio, Giancarlo [1 ]
Russo, Maria Giovanna [1 ]
Calabro, Raffaele [1 ]
机构
[1] Univ Naples 2, Dept Cardiol, Monaldi Hosp, Naples, Italy
关键词
Pulmonary arterial hypertension; Congenital heart disease; Association therapy; IMPROVES FUNCTIONAL-CAPACITY; ORAL SILDENAFIL; COMBINATION THERAPY; INHALED ILOPROST; CLINICAL-TRIAL; ADULT PATIENTS; 6-MINUTE WALK; OPEN-LABEL; EFFICACY; TOLERABILITY;
D O I
10.1016/j.ijcard.2010.10.051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The aim of the present study was to evaluate the safety, tolerability, clinical and haemodynamic impact of add-on sildenafil in patients with congenital heart disease (CHD)-related pulmonary arterial hypertension (PAH) and Eisenmenger physiology after failure of oral bosentan therapy. Methods: Thirty-two patients with CHD-related PAH (14 male, mean age 37.1 +/- 13.7 years) treated with oral bosentan underwent right heart catheterization (RHC) for clinical worsening. After RHC, all patients received oral sildenafil 20 mg thrice daily in addition to bosentan. Clinical status, resting transcutaneous oxygen saturation (SpO(2)), 6-minute walk test (6MWT), serology and RHC were assessed at baseline (before add-on sildenafil) and after 6 months of combination therapy. Results: Twelve patients had ventricular septal defect, 8 atrio-ventricular canal, 6 single ventricle, and 6 atrial septal defect. Twenty-eight/32 had Eisenmenger physiology and 4 (all with atrial septal defect) did not. All patients well tolerated combination therapy. After 6 months of therapy, an improvement in clinical status (WHO functional class 2.1 +/- 0.4 vs 2.9 +/- 0.3; P=0.042), 6-minute walk distance (360 +/- 51 vs 293 +/- 68 m; P=0.005), SpO(2) at the end of the 6MWT (72 +/- 10 vs 63 +/- 15%; P=0.047), Borg score (2.9 +/- 1.5 vs 4.4 +/- 2.3; P=0.036), serology (pro-brain natriuretic peptide 303 +/- 366 vs 760 +/- 943 pg/ml; P=0.008) and haemodynamics (pulmonary blood flow 3.4 +/- 1.0 vs 3.1 +/- 1.2 l/min/m(2), P=0.002; pulmonary vascular resistances index 19 +/- 9 vs 24 +/- 16 WU/m(2), P=0.003) was observed. Conclusions: Addition of sildenafil in adult patients with CHD-related PAH and Eisenmenger syndrome after oral bosentan therapy failure is safe and well tolerated at 6-month follow-up, resulting in a significant improvement in clinical status, effort SpO(2), exercise tolerance and haemodynamics. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
下载
收藏
页码:378 / 382
页数:5
相关论文
共 50 条
  • [11] Pulmonary hypertension secondary to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical and haemodynamic impact of oral bosentan
    D'alto, M.
    Vizza, C. D.
    Sarubbi, B.
    Santoro, G.
    Badagliacca, R.
    Argiento, P.
    Poscia, R.
    Calabro, R.
    EUROPEAN HEART JOURNAL, 2006, 27 : 624 - 624
  • [12] Eisenmenger syndrome and pulmonary arterial hypertension in adults with congenital heart disease
    Gatzoulis, Michael A.
    Barst, Robyn
    Fineman, Jeffrey
    Galie, Nazzareno
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 : S19 - S25
  • [13] Echocardiographic assessment for cardiopulmonary function in patients with congenital heart disease-related pulmonary arterial hypertension
    Yang, Lifang
    Luo, Dongling
    Huang, Taoran
    Li, Xiaoshan
    Zhang, Guolin
    Zhang, Caojin
    Fei, Hongwen
    BMC PULMONARY MEDICINE, 2024, 24 (01):
  • [14] EFFICACY AND SAFETY OF BOSENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION SECONDARY TO CONGENITAL HEART DISEASE
    Meng Lili
    Zhu Xianyang
    Zhang Duanzhen
    HEART, 2013, 99 : A42 - A42
  • [15] Eisenmenger syndrome and other types of pulmonary arterial hypertension related to adult congenital heart disease
    Favoccia, Carla
    Constantine, Andrew H.
    Wort, Stephen J.
    Dimopoulos, Konstantinos
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2019, 17 (06) : 449 - 459
  • [16] Effect of bosentan in patients with pulmonary arterial hypertension related to congenital heart disease with and without Down's syndrome
    D'alto, M.
    Romeo, E.
    Argiento, P.
    Sarubbi, B.
    Scognamiglio, G.
    Grimaldi, N.
    Correra, A.
    Russo, M. G.
    Calabro, R.
    EUROPEAN HEART JOURNAL, 2010, 31 : 764 - 764
  • [17] Epoprostenol, bosentan and sildenafil combination for pulmonary arterial hypertension (PAH) in Eisenmenger syndrome: a case report
    Roustit, Matthieu
    Trivin, Caroline
    Allenet, Benoit
    Pison, Christophe
    Calop, Jean
    PHARMACY WORLD & SCIENCE, 2007, 29 (05): : 508 - 508
  • [18] Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension
    McLaughlin, Vallerie
    Channick, Richard N.
    Ghofrani, Hossein-Ardeschir
    Lemarie, Jean-Christophe
    Naeije, Robert
    Packer, Milton
    Souza, Rogerio
    Tapson, Victor F.
    Tolson, Jonathan
    Al Hiti, Hikmet
    Meyer, Gisela
    Hoeper, Marius M.
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46 (02) : 405 - 413
  • [19] Bosentan-sildenafil combination in the treatment of patients with severe pulmonary hypertension, and its effect on cardiac function
    Cui, Zhe
    Geng, Lin
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2021, 20 (12) : 2619 - 2624
  • [20] Effect of bosentan in children with pulmonary arterial hypertension associated with congenital heart disease
    Rosenzweig, E. Berman
    Ivy, D. D.
    Doran, A. K.
    Claussen, L. R.
    Yung, D.
    Widlitz, A. C.
    Abman, S.
    Barst, R. J.
    EUROPEAN HEART JOURNAL, 2006, 27 : 617 - 617